WEBULL
News
SXTPW
0.0398
-0.50%
-0.0002
Weekly Report: what happened at SXTPW last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at SXTPW last week (1117-1121)?
Weekly Report · 11/24 09:42
60 DEGREES PHARMACEUTICALS ANNOUNCES CLINICAL SITE NOW OPEN FOR PATIENT ENROLLMENT FOR THE B-FREE CHRONIC BABESIOSIS STUDY AT MOUNT SINAI ICAHN SCHOOL OF MEDICINE
Reuters · 11/21 13:01
Weekly Report: what happened at SXTPW last week (1110-1114)?
Weekly Report · 11/17 09:42
60 DEGREES PHARMACEUTICALS INC <SXTP.O>: H.C. WAINWRIGHT ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $6
Reuters · 11/14 11:14
U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66
Reuters · 11/14 09:48
60 Degrees Pharma Q3 net product revenue rises
Reuters · 11/13 19:00
Weekly Report: what happened at SXTPW last week (1103-1107)?
Weekly Report · 11/10 09:40
Weekly Report: what happened at SXTPW last week (1027-1031)?
Weekly Report · 11/03 09:40
Weekly Report: what happened at SXTPW last week (1020-1024)?
Weekly Report · 10/27 09:42
Weekly Report: what happened at SXTPW last week (1013-1017)?
Weekly Report · 10/20 09:40
BUZZ-60 Degrees jumps after first patient in tick-borne illness trial clears infection
Reuters · 10/15 12:18
60 DEGREES PHARMACEUTICALS INC - TO REQUEST TYPE B MEETING WITH FDA IN EARLY 2026
Reuters · 10/15 11:14
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
Barchart · 10/15 06:14
Weekly Report: what happened at SXTPW last week (1006-1010)?
Weekly Report · 10/13 09:41
60 Degrees Pharmaceuticals Inc held annual stockholders meeting
Reuters · 10/10 20:16
60 DEGREES PHARMACEUTICALS UNVEILS NAME OF CHRONIC BABESIOSIS CLINICAL TRIAL: B-FREE CHRONIC BABESIOSIS STUDY
Reuters · 10/09 11:04
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
Barchart · 10/09 06:04
Weekly Report: what happened at SXTPW last week (0929-1003)?
Weekly Report · 10/06 09:40
Weekly Report: what happened at SXTPW last week (0922-0926)?
Weekly Report · 09/29 09:40
More
Webull provides a variety of real-time SXTPW stock news. You can receive the latest news about 60 Degrees Pharm through multiple platforms. This information may help you make smarter investment decisions.
About SXTPW
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.